Tempus AI TEM has skyrocketed 21% in the last three days, fueled by news of a $200 million partnership with AstraZeneca AZN ...

Tempus AI has reported impressive growth, but some of the volatile quarterly numbers have chased off aggressive investors.

Acquisitions Reinforce Clinical and Data Infrastructure: Tempus AI’s 2025 acquisitions of Deep 6 AI and Ambry Genetics have expanded its clinical footprint to more than 750 sites and 30 million ...

The partners plan to build evidence packages that standardize comprehensive genomic profiling and other molecular testing ...

Marcy Richardson from Ambry Genetics discusses the importance of a new study that assessed the functional impact of thousands of BRCA2 variants, identifying those that may increase cancer risk. What ...

Aaron joins Freenome most recently from REALM IDx, Inc., where he served as CEO and president for nearly four years, overseeing its subsidiaries Ambry Genetics, Invicro and Konica Minolta REALM-Japan.